Nogales-Gaete J, Arriagada C
Servicio de Neurologia Hospital Barros Luco Trudean, Facultad de Medicina, Universidad de Chile, Santiago de Chile.
Rev Med Chil. 1996 May;124(5):597-604.
Despite the important achievements in clinical and experimental aspects of demylinating diseases and multiple sclerosis (MS), its pathogenesis still remains unknown. The most commonly held view is that it is an autoimmune disease, related in some way to a viral infection, that occurs in genetically susceptible basis. Based on this, many current treatments for MS are designed to modulate the immune response and interferons are an example. Only beta interferon (out of delta and gamma interferon) has a dose dependent efficacy in phase III clinical trials, as treatment for remitting-relapsing forms. It produces a reduction in exacerbation rates and in the burden of the disease, measured by Magnetic Resonance imaging. The clinical use of beta interferon considering the cost and large treatment period, must be cautious, reserving it only for confirmed remitting-relapsing modalities of MS. There is no clear cut evidence that beta interferon is useful for chronic-progressive MS.
尽管在脱髓鞘疾病和多发性硬化症（MS）的临床及实验方面取得了重要成果，但其发病机制仍然不明。最普遍的观点认为，它是一种自身免疫性疾病，在某种程度上与病毒感染有关，发生在遗传易感性基础上。基于此，目前许多针对MS的治疗方法旨在调节免疫反应，干扰素就是一个例子。在III期临床试验中，仅β干扰素（δ干扰素和γ干扰素中）对复发缓解型MS具有剂量依赖性疗效。通过磁共振成像测量，它能降低病情加重率和疾病负担。考虑到成本和较长的治疗周期，β干扰素的临床应用必须谨慎，仅保留用于确诊的复发缓解型MS。没有明确证据表明β干扰素对慢性进展型MS有用。
